Federal Supply Schedule 36F79723D0240
Award Date
9/30/23
Last Date to Order
9/29/28
Federal Agency
Veterans Integrated Service Network 12
Awardee
Dynavax Technologies Corporation
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Dynavax Technologies Corporation, a biopharmaceutical company focused on immune system responses. The contract, valued at $28,105,875.00, covers the provision of adult vaccines to support the CDC's national immunization programs. As a multiple-award IDC, the contract allows for the continued issuance of task orders to Dynavax over the performance period, which runs through June 30,...
This Other Transaction IDV was awarded by the Joint PEO Chemical and Biological Defense, a U.S. Department of Defense agency, to Dynavax Technologies Corporation. The $38.7 million IDV funds adaptive clinical trials focused on disease prevention and treatment, leveraging Dynavax's expertise in immunology and infectious disease research. As a prime contractor, Dynavax will provide specialized pharmaceutical products and services, including drugs, vaccines, and medical countermeasures, under...
Dynavax Technologies Corporation was awarded a single-award Indefinite Delivery Contract by the Centers for Disease Control and Prevention. The contract has a potential value of $27.4M to deliver adult vaccines in support of the CDC's national immunization programs. No set-asides were specified. Performance will take place through June 2021. Under this contract, Dynavax will provide a range of pharmaceutical products and services. This includes delivering adult vaccines to the CDC to support its...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Dynavax Technologies Corporation, a biopharmaceutical company focused on immune system responses for disease prevention and treatment. The $58.455 million multiple-award IDC has a period of performance through June 30, 2026 and is for the procurement of adult vaccines to support the CDC's national immunization programs. Dynavax, which has experience conducting clinical trials and...
The federal contract IDV awarded to Dynavax Technologies Corporation is an Other Transaction Agreement (OTA) with the purpose of developing medical countermeasures against pneumonic plague. The $29.8 million ceiling value OTA was awarded on December 20, 2024 by the Joint Program Executive Office for Chemical and Biological Defense, a Defense agency. Dynavax, a biopharmaceutical company focused on immune system responses, will leverage its expertise in conducting clinical trials and research...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an Indefinite Delivery Indefinite Quantity (IDIQ) contract worth up to $58,450,000 to Dynavax Technologies Corporation (Dynavax) for the purchase of various adult vaccines. The contract has a period of performance from July 1, 2024 to June 30, 2025 and is not set-aside. The required vaccine types include Hepatitis A, Hepatitis B, Hepatitis A&B combination, Herpes...
The Centers for Disease Control and Prevention (CDC) has awarded a $56.2 million Indefinite Delivery Indefinite Quantity (IDIQ) contract to Dynavax Technologies Corporation, a biopharmaceutical company, for the purchase of 12 standard adult vaccines. This contract will support the CDC's immunization awardees, including state health departments, in their adult immunization programs authorized under Section 317(j) of the Public Health Service Act. The contract has a one-year period of...
The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract to Dynavax Technologies Corporation, valued at up to $56,203,651.08, to supply various adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The vaccines to be delivered include hepatitis A, hepatitis B, hepatitis A & B combination, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, tetanus, reduced diphtheria toxoid...
The federal contract IDV award is a Federal Supply Schedule (FSS) contract under Schedule 65 IB, which covers Drugs, Pharmaceuticals, and Hematology Related Products. The contract was awarded to HLS Therapeutics Inc., a for-profit manufacturer, on July 1, 2022 by the Veterans Integrated Service Network 12 (VISN 12), a civilian agency of the U.S. federal government. The contract has a ceiling value of $13,848,500.00 and a period of performance through June 30, 2027. It is a multiple award...
The federal contract IDV award described is a Federal Supply Schedule (FSS) contract under Schedule 65 I B Drugs, Pharmaceuticals, & Hematology Related Products, awarded to Syndax Pharmaceuticals, Inc. by the Department of Veterans Affairs. The contract has a ceiling value of $25,000.00 and a period of performance from February 1, 2025 to July 31, 2025. The contract aims to procure various pharmaceutical products and hematology-related supplies for the Veterans Integrated Service Network 12....